BioCryst to Report First Quarter 2025 Financial Results on May 5

4/21/25 7:00:19 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BCRX alert in real time by email

RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

John Bluth

+1 919 859 7910

[email protected]

Get the next $BCRX alert in real time by email

Recent Analyst Ratings for

$BCRX

Date	Price Target	Rating	Analyst
4/29/2025	$20.00	Overweight	Cantor Fitzgerald
2/25/2025	$15.00	Outperform	Wedbush
11/20/2023	$10.00	Overweight	JP Morgan
9/18/2023	$9.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
8/4/2023	$11.00	Hold → Buy	Jefferies
7/13/2023	$10.00	Neutral → Buy	BofA Securities
2/22/2023	$14.00	Hold → Buy	Needham
11/2/2022	$14.00 → $16.00	In-line → Outperform	Evercore ISI

More analyst ratings

BioCryst to Report First Quarter 2025 Financial Results on May 5

Chat with this insight

Recent Analyst Ratings for $BCRX

$BCRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

$BCRX Press Releases

Fastest customizable press release news feed in the world

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

$BCRX SEC Filings

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$BCRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Sanders Machelle was granted 12,500 shares, increasing direct ownership by 45% to 40,242 units (SEC Form 4)

Director Milano Vincent was granted 12,500 shares, increasing direct ownership by 16% to 89,760 units (SEC Form 4)

Director Mckee Amy E was granted 12,500 shares, increasing direct ownership by 45% to 40,331 units (SEC Form 4)

$BCRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

Wedbush initiated coverage on BioCryst Pharma with a new price target

JP Morgan resumed coverage on BioCryst Pharma with a new price target

$BCRX Leadership Updates

Live Leadership Updates

BioCryst Appoints Steve Frank to Board of Directors

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

$BCRX Financials

Live finance-specific insights

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

$BCRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Recent Analyst Ratings for
$BCRX

$BCRX
Insider Purchases

$BCRX
Press Releases

$BCRX
SEC Filings

$BCRX
Insider Trading

$BCRX
Analyst Ratings

$BCRX
Leadership Updates

$BCRX
Financials

$BCRX
Large Ownership Changes